​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences (NBIX) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $170.36, with a high of $195.00 and a low of $140.00. This represents a 33.32% increase from the last price of $127.78.

$115 $131 $147 $163 $179 $195 High: $195 Avg: $170.36 Low: $140 Last Closed Price: $127.78

NBIX Stock Rating

Neurocrine Biosciences stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (86.11%), 5 Hold (13.89%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 0 5 31 Strong Sell Sell Hold Buy Strong Buy

NBIX Price Target Upside V Benchmarks

TypeNameUpside
StockNeurocrine Biosciences33.32%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks25.21%

Price Target Trends

1M3M12M
# Anlaysts31329
Avg Price Target$165.00$175.46$173.83
Last Closing Price$127.78$127.78$127.78
Upside/Downside29.13%37.31%36.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 264194--27
Feb, 264194--27
Jan, 265193--27
Dec, 255193--27
Nov, 256183--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2026Josh SchimmerCantor Fitzgerald$195.00$130.3949.55%52.61%
Feb 23, 2026Wolfe Research$160.00$128.3824.63%25.22%
Feb 17, 2026Danielle BrillTruist Financial$140.00$128.988.54%9.56%
Feb 12, 2026Needham$185.00$125.3847.55%44.78%
Feb 12, 2026Wedbush$151.00$125.0920.71%18.17%
Feb 12, 2026Morgan Stanley$173.00$126.0437.26%35.39%
Feb 12, 2026H.C. Wainwright$192.00$137.4439.70%50.26%
Jan 23, 2026UBS$178.00$137.3729.58%39.30%
Jan 08, 2026Truist Financial$169.00$140.6220.18%32.26%
Jan 08, 2026Morgan Stanley$175.00$140.6224.45%36.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 24, 2026RBC CapitalOutperformOutperformhold
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 12, 2026WedbushOutperformOutperformhold
Feb 12, 2026CitigroupBuyBuyhold
Jan 05, 2026UBSBuyBuyhold
Dec 17, 2025H.C. WainwrightBuyBuyhold
Dec 17, 2025JefferiesBuyBuyhold
Dec 17, 2025BMO CapitalMarket PerformMarket Performhold
Dec 08, 2025RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$1.61$2.56$3.40$4.81---
Avg Forecast$1.78$2.22$2.56$4.05$6.40$8.65$11.24$14.00
High Forecast$1.87$2.34$2.94$4.34$7.44$11.63$15.31$14.86
Low Forecast$1.66$2.05$1.72$3.74$4.77$6.06$7.52$12.83
Surprise %-46.63%-27.48%--16.05%-24.84%---

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.13B$1.49B$1.89B$2.36B$2.86B---
Avg Forecast$1.14B$1.48B$1.89B$2.36B$2.77B$3.24B$3.68B$4.19B
High Forecast$1.18B$1.55B$1.90B$2.37B$2.84B$3.26B$3.71B$4.38B
Low Forecast$1.08B$1.40B$1.77B$2.34B$2.58B$3.22B$3.65B$3.92B
Surprise %-0.35%0.29%-0.12%-0.11%3.23%---

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.60M$154.50M$249.70M$341.30M$478.60M---
Avg Forecast$110.42M$4.14M$249.70M$385.90M$637.97M$898.75M$1.20B$1.41B
High Forecast$138.10M$25.12M$1.67B$438.60M$751.03M$1.18B$1.55B$1.50B
Low Forecast$82.73M$-16.85M$-1.17B$378.03M$482.22M$611.63M$759.47M$1.30B
Surprise %-18.85%3635.85%--11.56%-24.98%---

NBIX Forecast FAQ

Is Neurocrine Biosciences stock a buy?

Neurocrine Biosciences stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurocrine Biosciences is a favorable investment for most analysts.

What is Neurocrine Biosciences's price target?

Neurocrine Biosciences's price target, set by 36 Wall Street analysts, averages $170.36 over the next 12 months. The price target range spans from $140 at the low end to $195 at the high end, suggesting a potential 33.32% change from the previous closing price of $127.78.

How does Neurocrine Biosciences stock forecast compare to its benchmarks?

Neurocrine Biosciences's stock forecast shows a 33.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (25.21%).

What is the breakdown of analyst ratings for Neurocrine Biosciences over the past three months?

  • March 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 18.52% Strong Buy, 70.37% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Neurocrine Biosciences’s EPS forecast?

Neurocrine Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $8.65, marking a 79.83% increase from the reported $4.81 in 2025. Estimates for the following years are $11.24 in 2027, and $14 in 2028.

What is Neurocrine Biosciences’s revenue forecast?

Neurocrine Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $3.24B, reflecting a 13.23% increase from the reported $2.86B in 2025. The forecast for 2027 is $3.68B, and $4.19B for 2028.

What is Neurocrine Biosciences’s net income forecast?

Neurocrine Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $898.75M, representing an 87.79% increase from the reported $478.6M in 2025. Projections indicate $1.2B in 2027, and $1.41B in 2028.